Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Breakthrough in pancreatic cancer treatment: Inhibiting specific enzymes slows tumor progression

Study demonstrates that inhibiting stromal class I histone deacetylases (HDACs) can effectively slow down pancreatic cancer progression, shedding light on a new therapeutic approach targeting the tumor microenvironment.

10 Dec 2023

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.

8 Dec 2023

Biden wants states to ensure Obamacare plans cover enough doctors and hospitals

The Biden administration plans to push states to boost oversight of the number of doctors, hospitals, and other health providers insurers cover in Obamacare plans, under rules proposed in November.

6 Dec 2023

FDA clears Beckman Coulter Life Sciences AQUIOS STEM System for stem cell analysis

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has received 510(k) clearance from the Food and Drug Administration (FDA) to distribute its popular AQUIOS STEM System in the United States.

From Beckman Coulter Life Sciences 4 Dec 2023

Scientists unmask molecule that fuels leukemia growth

In a study published in the journal Genes & Diseases, researchers from Beckman Research Institute of City of Hope, explored the impact of m6A modification on the maturation process of precursor microRNAs (pre-miRNAs) and its potential role in tumorigenesis.

4 Dec 2023

Scientists uncover new mechanism by which leukemia cells exploit cellular recycling process

In a recent study, scientists led by Professor Stefan Müller from Goethe University's Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML.

4 Dec 2023

New approach enhances CAR T-cell therapy for solid tumors

Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for pediatric patients with relapsed and recurrent leukemia.

30 Nov 2023

Scientists uncover new therapeutic targets for high-risk pediatric leukemia

Scientists at St. Jude Children's Research Hospital comprehensively identified genes directly regulated by a protein associated with high-risk pediatric leukemias.

28 Nov 2023

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)-;two related blood diseases that disproportionally strike older adults-;are notoriously difficult to treat and associated with high relapse rates.

28 Nov 2023

RNA-based therapy shows promise for treating leukemia in animal models

Each year, about 13,000 people in Deutschland are diagnosed with leukemia, an umbrella term that encompasses various forms of blood cancer.

27 Nov 2023

Genetic vulnerability of leukemia cells uncovered

Leukemia is the most common type of cancer in children. Treatment involves intensive chemotherapy, which has severe side effects due to its non-specific mode of action.

22 Nov 2023

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

Findings from St. Jude Children's Research Hospital are moving the field of cancer immunotherapy one step closer to treating brain and solid tumors.

21 Nov 2023

UT Arlington researchers develop improved model for predicting cancer cure rates

With the rapid development in computing power over the past few decades, machine-learning (ML) techniques have become popular in medical settings as a way to predict survival rates and life expectancies among patients diagnosed with diseases such as cancer, heart disease, stroke, and, more recently, COVID-19.

20 Nov 2023

Leukemia News and Research

Further Reading

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Breakthrough in pancreatic cancer treatment: Inhibiting specific enzymes slows tumor progression

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

Biden wants states to ensure Obamacare plans cover enough doctors and hospitals

FDA clears Beckman Coulter Life Sciences AQUIOS STEM System for stem cell analysis

Scientists unmask molecule that fuels leukemia growth

Scientists uncover new mechanism by which leukemia cells exploit cellular recycling process

New approach enhances CAR T-cell therapy for solid tumors

Scientists uncover new therapeutic targets for high-risk pediatric leukemia

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

RNA-based therapy shows promise for treating leukemia in animal models

Genetic vulnerability of leukemia cells uncovered

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

UT Arlington researchers develop improved model for predicting cancer cure rates

Pigeon virus causes fatal neurological disease in young leukemia patient

Scientists uncover "genomic tug of war" that influences chemotherapy's effectiveness

Gene splicing determines CD20 levels and response to monoclonal antibody therapy

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News